Literature DB >> 23404393

Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian.

Tatiana Tatarinova1, Michael Neely, Jay Bartroff, Michael van Guilder, Walter Yamada, David Bayard, Roger Jelliffe, Robert Leary, Alyona Chubatiuk, Alan Schumitzky.   

Abstract

Population pharmacokinetic (PK) modeling methods can be statistically classified as either parametric or nonparametric (NP). Each classification can be divided into maximum likelihood (ML) or Bayesian (B) approaches. In this paper we discuss the nonparametric case using both maximum likelihood and Bayesian approaches. We present two nonparametric methods for estimating the unknown joint population distribution of model parameter values in a pharmacokinetic/pharmacodynamic (PK/PD) dataset. The first method is the NP Adaptive Grid (NPAG). The second is the NP Bayesian (NPB) algorithm with a stick-breaking process to construct a Dirichlet prior. Our objective is to compare the performance of these two methods using a simulated PK/PD dataset. Our results showed excellent performance of NPAG and NPB in a realistically simulated PK study. This simulation allowed us to have benchmarks in the form of the true population parameters to compare with the estimates produced by the two methods, while incorporating challenges like unbalanced sample times and sample numbers as well as the ability to include the covariate of patient weight. We conclude that both NPML and NPB can be used in realistic PK/PD population analysis problems. The advantages of one versus the other are discussed in the paper. NPAG and NPB are implemented in R and freely available for download within the Pmetrics package from www.lapk.org.

Entities:  

Mesh:

Year:  2013        PMID: 23404393      PMCID: PMC3630269          DOI: 10.1007/s10928-013-9302-8

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  13 in total

1.  Achieving target goals most precisely using nonparametric compartmental models and "multiple model" design of dosage regimens.

Authors:  R Jelliffe; D Bayard; M Milman; M Van Guilder; A Schumitzky
Journal:  Ther Drug Monit       Date:  2000-06       Impact factor: 3.681

2.  Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models.

Authors:  Paul G Baverel; Radojka M Savic; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-11-13       Impact factor: 2.745

3.  A semi-parametric Bayesian approach to average bioequivalence.

Authors:  Pulak Ghosh; Gary L Rosner
Journal:  Stat Med       Date:  2007-03-15       Impact factor: 2.373

4.  Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.

Authors:  Aida Bustad; Dimiter Terziivanov; Robert Leary; Ruediger Port; Alan Schumitzky; Roger Jelliffe
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  Nonlinear Random Effects Mixture Models: Maximum Likelihood Estimation via the EM Algorithm.

Authors:  Xiaoning Wang; Alan Schumitzky; David Z D'Argenio
Journal:  Comput Stat Data Anal       Date:  2007-08-15       Impact factor: 1.681

Review 6.  Estimating population kinetics.

Authors:  S L Beal; L B Sheiner
Journal:  Crit Rev Biomed Eng       Date:  1982

7.  Bayesian population pharmacokinetic and pharmacodynamic analyses using mixture models.

Authors:  G L Rosner; P Müller
Journal:  J Pharmacokinet Biopharm       Date:  1997-04

8.  Kullback-Leibler Markov chain Monte Carlo--a new algorithm for finite mixture analysis and its application to gene expression data.

Authors:  Tatiana Tatarinova; John Bouck; Alan Schumitzky
Journal:  J Bioinform Comput Biol       Date:  2008-08       Impact factor: 1.122

9.  Population Pharmacokinetic/Pharmacodyanamic Mixture Models via Maximum a Posteriori Estimation.

Authors:  Xiaoning Wang; Alan Schumitzky; David Z D'Argenio
Journal:  Comput Stat Data Anal       Date:  2009-10-01       Impact factor: 1.681

10.  Flexible random-effects models using Bayesian semi-parametric models: applications to institutional comparisons.

Authors:  D I Ohlssen; L D Sharples; D J Spiegelhalter
Journal:  Stat Med       Date:  2007-04-30       Impact factor: 2.373

View more
  36 in total

1.  Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats.

Authors:  Nathaniel J Rhodes; Walter C Prozialeck; Thomas P Lodise; Natarajan Venkatesan; J Nicholas O'Donnell; Gwendolyn Pais; Cameron Cluff; Peter C Lamar; Michael N Neely; Anil Gulati; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

2.  Are vancomycin trough concentrations adequate for optimal dosing?

Authors:  Michael N Neely; Gilmer Youn; Brenda Jones; Roger W Jelliffe; George L Drusano; Keith A Rodvold; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2013-10-28       Impact factor: 5.191

3.  Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy.

Authors:  Claire Roger; Steven C Wallis; Laurent Muller; Gilbert Saissi; Jeffrey Lipman; Jean-Yves Lefrant; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

4.  Reevaluation of ceftazidime dosing recommendations in patients on continuous ambulatory peritoneal dialysis.

Authors:  Katie E Cardone; Darren W Grabe; Evan J Zasowski; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

5.  Population modeling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs.

Authors:  L Lalande; L Bourguignon; S Bihari; P Maire; M Neely; R Jelliffe; S Goutelle
Journal:  Antimicrob Agents Chemother       Date:  2015-06-15       Impact factor: 5.191

6.  Pharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux hemodialysis.

Authors:  Angela S Loo; Michael Neely; Evan J Anderson; Cybele Ghossein; Milena M McLaughlin; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

7.  Influence of renal function estimation on pharmacokinetic modeling of vancomycin in elderly patients.

Authors:  Anaïs Glatard; Laurent Bourguignon; Roger W Jelliffe; Pascal Maire; Michael N Neely; Sylvain Goutelle
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

8.  Vancomycin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis.

Authors:  Salmaan Kanji; Jason A Roberts; Jiao Xie; Sheryl Zelenitsky; Swapnil Hiremath; Guijun Zhang; Irene Watpool; Rebecca Porteous; Rakesh Patel
Journal:  Clin Pharmacokinet       Date:  2020-03       Impact factor: 6.447

9.  Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens.

Authors:  Thomas Tängdén; Pier Giorgio Cojutti; Jason A Roberts; Federico Pea
Journal:  Clin Pharmacokinet       Date:  2018-11       Impact factor: 6.447

10.  Comparative Population Plasma and Tissue Pharmacokinetics of Micafungin in Critically Ill Patients with Severe Burn Injuries and Patients with Complicated Intra-Abdominal Infection.

Authors:  A García-de-Lorenzo; S Luque; S Grau; A Agrifoglio; L Cachafeiro; E Herrero; M J Asensio; S M Sánchez; J A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.